Excitatory amino acid receptor ligands: resolution, absolute stereochemistry, and enantiopharmacology of 2-amino-3-(4-butyl-3-hydroxyisoxazol-5-yl)propionic acid

Journal of Medicinal Chemistry
Tommy N JohansenL Brehm

Abstract

(RS)-2-Amino-3-(4-butyl-3-hydroxyisoxazol-5-yl)propionic acid (Bu-HIBO, 6) has previously been shown to be an agonist at (RS)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic acid (AMPA) receptors and an inhibitor of CaCl2-dependent [3H]-(S)-glutamic acid binding (J. Med. Chem. 1992, 35, 3512-3519). To elucidate the pharmacological significance of this latter binding affinity, which is also shown by quisqualic acid (3) but not by AMPA, we have now resolved Bu-HIBO via diastereomeric salt formation using the diprotected Bu-HIBO derivative 11 and the enantiomers of 1-phenylethylamine (PEA). The absolute stereochemistry of (S)-Bu-HIBO (7) (ee = 99.0%) and (R)-Bu-HIBO (8) (ee > 99.6%) were established by an X-ray crystallographic analysis of compound 15, a salt of (R)-PEA, and diprotected 8. Circular dichroism spectra of 7 and 8 were recorded. Whereas 7 (IC50 = 0.64 microM) and 8 (IC50 = 0.57 microM) were equipotent as inhibitors of CaCl2-dependent [3H]-(S)-glutamic acid binding, neither enantiomer showed significant affinity for the synaptosomal (S)-glutamic acid uptake system(s). AMPA receptor affinity (IC50 = 0.48 microM) and agonism (EC50 = 17 microM) were shown to reside exclusively in the S-enantiomer, 7. Compounds 7 and ...Continue Reading

References

Jan 1, 1992·Neuron·Y TanabeS Nakanishi
Jul 1, 1992·Trends in Pharmacological Sciences·B Sommer, P H Seeburg
Sep 1, 1990·The British Journal of Psychiatry : the Journal of Mental Science·D M Bowen
Jan 1, 1990·Medicinal Research Reviews·J J Hansen, P Krogsgaard-Larsen
Jan 1, 1989·Clinical Neuropharmacology·S Garattini, T Mennini
Feb 28, 1985·Neuroscience Letters·T Honoré, M Nielsen
Feb 1, 1985·British Journal of Pharmacology·N L Harrison, M A Simmonds
Mar 6, 1980·Nature·P Krogsgaard-LarsenD Lodge
Jul 1, 1994·The European Journal of Neuroscience·J LermaF Somohano
Dec 20, 1994·Neuroreport·C ThomsenP D Suzdak
Jan 1, 1994·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·U MadsenP Krogsgaard-Larsen
Jan 1, 1993·Schizophrenia Bulletin·J Ułas, C W Cotman
May 1, 1996·Neuropharmacology·C L WillisR J Bridges

❮ Previous
Next ❯

Citations

Mar 27, 2004·European Journal of Pharmacology·Henrik T VestergaardBjarke Ebert
Aug 8, 1998·European Journal of Pharmacology·H Bräuner-OsborneP Krogsgaard-Larsen
Jan 1, 2010·Acta Crystallographica. Section E, Structure Reports Online·María-Guadalupe Hernández LinaresSylvain Bernès
Mar 1, 2012·European Journal of Pharmacology·Suzanne L HansenHenrik T Vestergaard
Jul 14, 2000·Journal of Medicinal Chemistry·H Bräuner-OsborneP Krogsgaard-Larsen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.

Blood Brain Barrier Regulation in Health & Disease

The blood brain barrier is essential in regulating the movement of molecules and substances in and out of the brain. Disruption to the blood brain barrier and changes in permeability allow pathogens and inflammatory molecules to cross the barrier and may play a part in the pathogenesis of neurodegenerative disorders. Here is the latest research in this field.